PDCD1 and cancer: Some researchers have proposed that the CRISPR/Cas9 system can be used to modify differentiated T cells in patients to target the expression of PD-1 on T cells, so that CD4 T cells can be re-targeted and destroy cancer cells (Schumann et al., 2015).